Protagonist and Takeda Present 52-Week Results of Rusfertide Study
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Sustained Efficacy: In the VERIFY study, 61.9% of patients maintained a clinical response without phlebotomy eligibility at 52 weeks, demonstrating rusfertide's long-term effectiveness in treating polycythemia vera, which could redefine current treatment standards.
- Good Safety Profile: Rusfertide's safety over 52 weeks was consistent with prior observations, with injection site reactions occurring in 47.4% of patients, indicating good tolerability that supports long-term use in patients.
- Significant Reduction in Phlebotomy Needs: In the THRIVE study, rusfertide reduced the annual phlebotomy rate from 9.2 to 0.7, achieving a 13-fold decrease that significantly enhances patient quality of life and lowers thrombotic risks.
- Clinical Decision Support: The study results will be presented at the American Society of Hematology annual meeting, further supporting rusfertide's potential as a new treatment option for polycythemia vera, expected to advance the NDA submission process to the FDA.
PTGX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PTGX
Wall Street analysts forecast PTGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 87.31 USD with a low forecast of 65.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 87.330
Low
65.00
Averages
87.31
High
112.00
Current: 87.330
Low
65.00
Averages
87.31
High
112.00
Goldman Sachs
Neutral
maintain
$47 -> $65
2025-11-10
Reason
Goldman Sachs
Price Target
$47 -> $65
2025-11-10
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Protagonist Therapeutics (PTGX) to $65 from $47 and keeps a Neutral rating on the shares. Protagonist reported Q3 results with GAAP EPS of (62c), supported by $678.8M in cash expected to fund operations through year end 2028 without additional capital raises, the analyst tells investors in a research note. Despite a 20% stock lift following a Wall Street Journal report on potential Johnson & Johnson (JNJ) interest, the current price appears disconnected from fundamentals, and remaining unpartnered assets remain early-stage, the firm adds.
Citi
Buy
maintain
$96 -> $98
2025-11-10
Reason
Citi
Price Target
$96 -> $98
2025-11-10
maintain
Buy
Reason
Citi raised the firm's price target on Protagonist Therapeutics to $98 from $96 and keeps a Buy rating on the shares.
JPMorgan
Brian Cheng
Overweight
maintain
$68 -> $81
2025-11-07
Reason
JPMorgan
Brian Cheng
Price Target
$68 -> $81
2025-11-07
maintain
Overweight
Reason
JPMorgan analyst Brian Cheng raised the firm's price target on Protagonist Therapeutics to $81 from $68 and keeps an Overweight rating on the shares.
Clear Street
Buy
upgrade
$74 -> $91
2025-11-07
Reason
Clear Street
Price Target
$74 -> $91
2025-11-07
upgrade
Buy
Reason
Clear Street raised the firm's price target on Protagonist Therapeutics to $91 from $74 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
See All Ratings
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What does the VERIFY study reveal about rusfertide's long-term effectiveness?
How does rusfertide's safety profile compare to previous observations?
How might the 52-week results impact rusfertide's FDA approval timeline?
What are the chances of rusfertide becoming the standard treatment for polycythemia vera?